See what’s new.
Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-generation treatment for acute ischemic stroke.
Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma
Adaptin Bio is a Duke start-up based around glioblastoma-related technologies developed in the lab of Dr. John Sampson (Neurosurgery, SOM).
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Lindy Biosciences is a Duke University start-up run by CEO Deborah Bitterfield (PhD MEMS, Pratt) based on technology developed in the lab of Professor Emeritus David Needham (MEMS, Pratt).
New therapy for glioma receives FDA approval, leveraging cancer research conducted at Johns Hopkins & Duke University
Drs. Darell Bigner and Hai Yan (Neurosurgery, SOM) and colleagues identified the genetic mutation targeted by this new drug. Dr. Katherine Peters (Neurosurgery, SOM) was lead investigator in the clinical trials.
The Kardashians Take Longevity Test that Reveals Biological Age in ‘The Kardashians’ Upcoming Season Finale
Kardashians use biological age algorithm technology developed by Professors Terrie Moffitt & Avshalom Caspi (Psychology & Neuroscience, SOM) and licensed to TruDiagnostics.
VQ Biomedical receives $750K grant from BARDA / ASPR / HHS
VQ Biomedical is a start-up resulting from the collaboration of Assistant Professor Tobias Straube (Pediatrics, SOM) and Research Scientist Stewart Farling (CEE, Pratt).
Meta Marketplace – Duke Magazine
Ideas from the lab of David Smith (ECE, Pratt) are showing up all over the place. Learn more about the lab's multiple spinouts.
Weird Science – Duke Magazine
Professor David Smith (ECE, Pratt) is a pioneer in the field of metamaterials – melding basic research and successful commercialization.
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
Uplizna, an antibody therapy for immune diseases, is based on technology licensed from Duke University, developed by the late Dr. Thomas Tedder (Immunology, SOM) and colleagues.